GRAD-COV2

GRAD-COV2 has been studied in 1 paper since 2021: 1 trial in people. The newest paper, Oct 27, 2021: “GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults”.

Intervention

1 paper studies it3 findingsUpdated

See all 1 papers on GRAD-COV2

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“seroconversion to spike protein and receptor binding domain was achieved in 43 of 44 young volunteers and in 45 of 45 older participants”
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adultsScience translational medicine2021doi:10.1126/scitranslmed.abj1996

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funders: Agence Nationale de la Recherche and 2 more
  • Human trial1

Studies in people

1 study gave GRAD-COV2 to people and measured what changed.

What changedDesignPeopleSource

up: Induces seroconversion43 of 44 young and 45 of 45 older participants

up: Induces neutralizing antibodies42 of 44 younger-age and 45 of 45 older-age volunteers

up: Induces T cell response89 of 90 participants

Trialfour weeks90 people18 to 85 years oldOlder adultsScience translational medicine, Oct 27, 2021

What did studies of GRAD-COV2 find?

3

Studies of GRAD-COV2 measured 3 outcomes: T cell response, neutralizing antibodies and seroconversion.

T cell response

upin humans1

1 study
  1. GRAD-COV2 induces T cell response in humans (89 of 90 participants).

    “GRAd-COV2 induced a robust and T helper 1 cell (TH1)–skewed T cell response against the spike protein in 89 of 90 participants from both age groups”

    Human trialthree escalating dosesfour weeksn = 90

    GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

    Science translational medicine

More on T cell response

Neutralizing antibodies

upin humans1

1 study
  1. GRAD-COV2 induces neutralizing antibodies in humans (42 of 44 younger-age and 45 of 45 older-age volunteers).

    “neutralizing antibodies were detected in 42 of 44 younger-age and 45 of 45 older-age volunteers”

    Human trialthree escalating dosesfour weeksn = 90

    GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

    Science translational medicine

More on Neutralizing antibodies

Seroconversion

upin humans1

1 study
  1. GRAD-COV2 induces seroconversion in humans (43 of 44 young and 45 of 45 older participants).

    “seroconversion to spike protein and receptor binding domain was achieved in 43 of 44 young volunteers and in 45 of 45 older participants”

    Human trialthree escalating dosesfour weeksn = 90

    GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

    Science translational medicine

More on Seroconversion

Latest